Global Tumor Immunotherapy Market Research Report 2022

Global Tumor Immunotherapy Market Research Report 2022

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Immunotherapy Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Tumor Infiltrating Lymphocyte (TIL) Treatment
1.2.3 Engineered T Cell Receptor (TCR) Therapy
1.2.4 Chimeric Antigen Receptor (CAR) T Cell Therapy
1.2.5 Natural Killer (NK) Cell Therapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Tumor Immunotherapy Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Biopharmaceutical Company
1.3.3 Hospital
1.3.4 Universities And Other Scientific Research Institutions
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Tumor Immunotherapy Market Perspective (2017-2028)
2.2 Tumor Immunotherapy Growth Trends by Region
2.2.1 Tumor Immunotherapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Tumor Immunotherapy Historic Market Size by Region (2017-2022)
2.2.3 Tumor Immunotherapy Forecasted Market Size by Region (2023-2028)
2.3 Tumor Immunotherapy Market Dynamics
2.3.1 Tumor Immunotherapy Industry Trends
2.3.2 Tumor Immunotherapy Market Drivers
2.3.3 Tumor Immunotherapy Market Challenges
2.3.4 Tumor Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor Immunotherapy Players by Revenue
3.1.1 Global Top Tumor Immunotherapy Players by Revenue (2017-2022)
3.1.2 Global Tumor Immunotherapy Revenue Market Share by Players (2017-2022)
3.2 Global Tumor Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tumor Immunotherapy Revenue
3.4 Global Tumor Immunotherapy Market Concentration Ratio
3.4.1 Global Tumor Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Immunotherapy Revenue in 2021
3.5 Tumor Immunotherapy Key Players Head office and Area Served
3.6 Key Players Tumor Immunotherapy Product Solution and Service
3.7 Date of Enter into Tumor Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor Immunotherapy Breakdown Data by Type
4.1 Global Tumor Immunotherapy Historic Market Size by Type (2017-2022)
4.2 Global Tumor Immunotherapy Forecasted Market Size by Type (2023-2028)
5 Tumor Immunotherapy Breakdown Data by Application
5.1 Global Tumor Immunotherapy Historic Market Size by Application (2017-2022)
5.2 Global Tumor Immunotherapy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Tumor Immunotherapy Market Size (2017-2028)
6.2 North America Tumor Immunotherapy Market Size by Country (2017-2022)
6.3 North America Tumor Immunotherapy Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Tumor Immunotherapy Market Size (2017-2028)
7.2 Europe Tumor Immunotherapy Market Size by Country (2017-2022)
7.3 Europe Tumor Immunotherapy Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tumor Immunotherapy Market Size (2017-2028)
8.2 Asia-Pacific Tumor Immunotherapy Market Size by Country (2017-2022)
8.3 Asia-Pacific Tumor Immunotherapy Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Tumor Immunotherapy Market Size (2017-2028)
9.2 Latin America Tumor Immunotherapy Market Size by Country (2017-2022)
9.3 Latin America Tumor Immunotherapy Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor Immunotherapy Market Size (2017-2028)
10.2 Middle East & Africa Tumor Immunotherapy Market Size by Country (2017-2022)
10.3 Middle East & Africa Tumor Immunotherapy Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Tumor Immunotherapy Introduction
11.1.4 Roche Revenue in Tumor Immunotherapy Business (2017-2022)
11.1.5 Roche Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Tumor Immunotherapy Introduction
11.2.4 Merck Revenue in Tumor Immunotherapy Business (2017-2022)
11.2.5 Merck Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Tumor Immunotherapy Introduction
11.3.4 Novartis Revenue in Tumor Immunotherapy Business (2017-2022)
11.3.5 Novartis Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Tumor Immunotherapy Introduction
11.4.4 Johnson & Johnson Revenue in Tumor Immunotherapy Business (2017-2022)
11.4.5 Johnson & Johnson Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Tumor Immunotherapy Introduction
11.5.4 GlaxoSmithKline Revenue in Tumor Immunotherapy Business (2017-2022)
11.5.5 GlaxoSmithKline Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Detail
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Tumor Immunotherapy Introduction
11.6.4 AbbVie Revenue in Tumor Immunotherapy Business (2017-2022)
11.6.5 AbbVie Recent Development
11.7 ELI Lilly
11.7.1 ELI Lilly Company Detail
11.7.2 ELI Lilly Business Overview
11.7.3 ELI Lilly Tumor Immunotherapy Introduction
11.7.4 ELI Lilly Revenue in Tumor Immunotherapy Business (2017-2022)
11.7.5 ELI Lilly Recent Development
11.8 Amgen
11.8.1 Amgen Company Detail
11.8.2 Amgen Business Overview
11.8.3 Amgen Tumor Immunotherapy Introduction
11.8.4 Amgen Revenue in Tumor Immunotherapy Business (2017-2022)
11.8.5 Amgen Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Detail
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Tumor Immunotherapy Introduction
11.9.4 AstraZeneca Revenue in Tumor Immunotherapy Business (2017-2022)
11.9.5 AstraZeneca Recent Development
11.10 Bristol-Mysers Squibb
11.10.1 Bristol-Mysers Squibb Company Detail
11.10.2 Bristol-Mysers Squibb Business Overview
11.10.3 Bristol-Mysers Squibb Tumor Immunotherapy Introduction
11.10.4 Bristol-Mysers Squibb Revenue in Tumor Immunotherapy Business (2017-2022)
11.10.5 Bristol-Mysers Squibb Recent Development
11.11 Kite Pharma
11.11.1 Kite Pharma Company Detail
11.11.2 Kite Pharma Business Overview
11.11.3 Kite Pharma Tumor Immunotherapy Introduction
11.11.4 Kite Pharma Revenue in Tumor Immunotherapy Business (2017-2022)
11.11.5 Kite Pharma Recent Development
11.12 Adaptimmune
11.12.1 Adaptimmune Company Detail
11.12.2 Adaptimmune Business Overview
11.12.3 Adaptimmune Tumor Immunotherapy Introduction
11.12.4 Adaptimmune Revenue in Tumor Immunotherapy Business (2017-2022)
11.12.5 Adaptimmune Recent Development
11.13 Altor Bioscience Corporation
11.13.1 Altor Bioscience Corporation Company Detail
11.13.2 Altor Bioscience Corporation Business Overview
11.13.3 Altor Bioscience Corporation Tumor Immunotherapy Introduction
11.13.4 Altor Bioscience Corporation Revenue in Tumor Immunotherapy Business (2017-2022)
11.13.5 Altor Bioscience Corporation Recent Development
11.14 Cellectis
11.14.1 Cellectis Company Detail
11.14.2 Cellectis Business Overview
11.14.3 Cellectis Tumor Immunotherapy Introduction
11.14.4 Cellectis Revenue in Tumor Immunotherapy Business (2017-2022)
11.14.5 Cellectis Recent Development
11.15 Juno Therapeutics
11.15.1 Juno Therapeutics Company Detail
11.15.2 Juno Therapeutics Business Overview
11.15.3 Juno Therapeutics Tumor Immunotherapy Introduction
11.15.4 Juno Therapeutics Revenue in Tumor Immunotherapy Business (2017-2022)
11.15.5 Juno Therapeutics Recent Development
11.16 Takara Bio
11.16.1 Takara Bio Company Detail
11.16.2 Takara Bio Business Overview
11.16.3 Takara Bio Tumor Immunotherapy Introduction
11.16.4 Takara Bio Revenue in Tumor Immunotherapy Business (2017-2022)
11.16.5 Takara Bio Recent Development
11.17 Unum Therapeutics
11.17.1 Unum Therapeutics Company Detail
11.17.2 Unum Therapeutics Business Overview
11.17.3 Unum Therapeutics Tumor Immunotherapy Introduction
11.17.4 Unum Therapeutics Revenue in Tumor Immunotherapy Business (2017-2022)
11.17.5 Unum Therapeutics Recent Development
11.18 Sunway
11.18.1 Sunway Company Detail
11.18.2 Sunway Business Overview
11.18.3 Sunway Tumor Immunotherapy Introduction
11.18.4 Sunway Revenue in Tumor Immunotherapy Business (2017-2022)
11.18.5 Sunway Recent Development
11.19 Junshi Bio
11.19.1 Junshi Bio Company Detail
11.19.2 Junshi Bio Business Overview
11.19.3 Junshi Bio Tumor Immunotherapy Introduction
11.19.4 Junshi Bio Revenue in Tumor Immunotherapy Business (2017-2022)
11.19.5 Junshi Bio Recent Development
11.20 Cinda Bio
11.20.1 Cinda Bio Company Detail
11.20.2 Cinda Bio Business Overview
11.20.3 Cinda Bio Tumor Immunotherapy Introduction
11.20.4 Cinda Bio Revenue in Tumor Immunotherapy Business (2017-2022)
11.20.5 Cinda Bio Recent Development
11.21 BeiGene
11.21.1 BeiGene Company Detail
11.21.2 BeiGene Business Overview
11.21.3 BeiGene Tumor Immunotherapy Introduction
11.21.4 BeiGene Revenue in Tumor Immunotherapy Business (2017-2022)
11.21.5 BeiGene Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Tumor Immunotherapy Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Tumor Infiltrating Lymphocyte (TIL) Treatment
Table 3. Key Players of Engineered T Cell Receptor (TCR) Therapy
Table 4. Key Players of Chimeric Antigen Receptor (CAR) T Cell Therapy
Table 5. Key Players of Natural Killer (NK) Cell Therapy
Table 6. Key Players of Other
Table 7. Global Tumor Immunotherapy Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Tumor Immunotherapy Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Tumor Immunotherapy Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Tumor Immunotherapy Market Share by Region (2017-2022)
Table 11. Global Tumor Immunotherapy Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Tumor Immunotherapy Market Share by Region (2023-2028)
Table 13. Tumor Immunotherapy Market Trends
Table 14. Tumor Immunotherapy Market Drivers
Table 15. Tumor Immunotherapy Market Challenges
Table 16. Tumor Immunotherapy Market Restraints
Table 17. Global Tumor Immunotherapy Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Tumor Immunotherapy Market Share by Players (2017-2022)
Table 19. Global Top Tumor Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunotherapy as of 2021)
Table 20. Ranking of Global Top Tumor Immunotherapy Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Tumor Immunotherapy Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Tumor Immunotherapy Product Solution and Service
Table 24. Date of Enter into Tumor Immunotherapy Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Tumor Immunotherapy Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Tumor Immunotherapy Revenue Market Share by Type (2017-2022)
Table 28. Global Tumor Immunotherapy Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Tumor Immunotherapy Revenue Market Share by Type (2023-2028)
Table 30. Global Tumor Immunotherapy Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Tumor Immunotherapy Revenue Market Share by Application (2017-2022)
Table 32. Global Tumor Immunotherapy Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Tumor Immunotherapy Revenue Market Share by Application (2023-2028)
Table 34. North America Tumor Immunotherapy Market Size by Country (2017-2022) & (US$ Million)
Table 35. North America Tumor Immunotherapy Market Size by Country (2023-2028) & (US$ Million)
Table 36. Europe Tumor Immunotherapy Market Size by Country (2017-2022) & (US$ Million)
Table 37. Europe Tumor Immunotherapy Market Size by Country (2023-2028) & (US$ Million)
Table 38. Asia-Pacific Tumor Immunotherapy Market Size by Region (2017-2022) & (US$ Million)
Table 39. Asia-Pacific Tumor Immunotherapy Market Size by Region (2023-2028) & (US$ Million)
Table 40. Latin America Tumor Immunotherapy Market Size by Country (2017-2022) & (US$ Million)
Table 41. Latin America Tumor Immunotherapy Market Size by Country (2023-2028) & (US$ Million)
Table 42. Middle East & Africa Tumor Immunotherapy Market Size by Country (2017-2022) & (US$ Million)
Table 43. Middle East & Africa Tumor Immunotherapy Market Size by Country (2023-2028) & (US$ Million)
Table 44. Roche Company Detail
Table 45. Roche Business Overview
Table 46. Roche Tumor Immunotherapy Product
Table 47. Roche Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 48. Roche Recent Development
Table 49. Merck Company Detail
Table 50. Merck Business Overview
Table 51. Merck Tumor Immunotherapy Product
Table 52. Merck Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 53. Merck Recent Development
Table 54. Novartis Company Detail
Table 55. Novartis Business Overview
Table 56. Novartis Tumor Immunotherapy Product
Table 57. Novartis Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 58. Novartis Recent Development
Table 59. Johnson & Johnson Company Detail
Table 60. Johnson & Johnson Business Overview
Table 61. Johnson & Johnson Tumor Immunotherapy Product
Table 62. Johnson & Johnson Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 63. Johnson & Johnson Recent Development
Table 64. GlaxoSmithKline Company Detail
Table 65. GlaxoSmithKline Business Overview
Table 66. GlaxoSmithKline Tumor Immunotherapy Product
Table 67. GlaxoSmithKline Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 68. GlaxoSmithKline Recent Development
Table 69. AbbVie Company Detail
Table 70. AbbVie Business Overview
Table 71. AbbVie Tumor Immunotherapy Product
Table 72. AbbVie Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 73. AbbVie Recent Development
Table 74. ELI Lilly Company Detail
Table 75. ELI Lilly Business Overview
Table 76. ELI Lilly Tumor Immunotherapy Product
Table 77. ELI Lilly Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 78. ELI Lilly Recent Development
Table 79. Amgen Company Detail
Table 80. Amgen Business Overview
Table 81. Amgen Tumor Immunotherapy Product
Table 82. Amgen Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 83. Amgen Recent Development
Table 84. AstraZeneca Company Detail
Table 85. AstraZeneca Business Overview
Table 86. AstraZeneca Tumor Immunotherapy Product
Table 87. AstraZeneca Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 88. AstraZeneca Recent Development
Table 89. Bristol-Mysers Squibb Company Detail
Table 90. Bristol-Mysers Squibb Business Overview
Table 91. Bristol-Mysers Squibb Tumor Immunotherapy Product
Table 92. Bristol-Mysers Squibb Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 93. Bristol-Mysers Squibb Recent Development
Table 94. Kite Pharma Company Detail
Table 95. Kite Pharma Business Overview
Table 96. Kite Pharma Tumor ImmunotherapyProduct
Table 97. Kite Pharma Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 98. Kite Pharma Recent Development
Table 99. Adaptimmune Company Detail
Table 100. Adaptimmune Business Overview
Table 101. Adaptimmune Tumor ImmunotherapyProduct
Table 102. Adaptimmune Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 103. Adaptimmune Recent Development
Table 104. Altor Bioscience Corporation Company Detail
Table 105. Altor Bioscience Corporation Business Overview
Table 106. Altor Bioscience Corporation Tumor ImmunotherapyProduct
Table 107. Altor Bioscience Corporation Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 108. Altor Bioscience Corporation Recent Development
Table 109. Cellectis Company Detail
Table 110. Cellectis Business Overview
Table 111. Cellectis Tumor ImmunotherapyProduct
Table 112. Cellectis Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 113. Cellectis Recent Development
Table 114. Juno Therapeutics Company Detail
Table 115. Juno Therapeutics Business Overview
Table 116. Juno Therapeutics Tumor ImmunotherapyProduct
Table 117. Juno Therapeutics Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 118. Juno Therapeutics Recent Development
Table 119. Takara Bio Company Detail
Table 120. Takara Bio Business Overview
Table 121. Takara Bio Tumor ImmunotherapyProduct
Table 122. Takara Bio Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 123. Takara Bio Recent Development
Table 124. Unum Therapeutics Company Detail
Table 125. Unum Therapeutics Business Overview
Table 126. Unum Therapeutics Tumor ImmunotherapyProduct
Table 127. Unum Therapeutics Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 128. Unum Therapeutics Recent Development
Table 129. Sunway Company Detail
Table 130. Sunway Business Overview
Table 131. Sunway Tumor ImmunotherapyProduct
Table 132. Sunway Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 133. Sunway Recent Development
Table 134. Junshi Bio Company Detail
Table 135. Junshi Bio Business Overview
Table 136. Junshi Bio Tumor ImmunotherapyProduct
Table 137. Junshi Bio Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 138. Junshi Bio Recent Development
Table 139. Cinda Bio Company Detail
Table 140. Cinda Bio Business Overview
Table 141. Cinda Bio Tumor ImmunotherapyProduct
Table 142. Cinda Bio Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 143. Cinda Bio Recent Development
Table 144. BeiGene Company Detail
Table 145. BeiGene Business Overview
Table 146. BeiGene Tumor ImmunotherapyProduct
Table 147. BeiGene Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)
Table 148. BeiGene Recent Development
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Tumor Immunotherapy Market Share by Type: 2021 VS 2028
Figure 2. Tumor Infiltrating Lymphocyte (TIL) Treatment Features
Figure 3. Engineered T Cell Receptor (TCR) Therapy Features
Figure 4. Chimeric Antigen Receptor (CAR) T Cell Therapy Features
Figure 5. Natural Killer (NK) Cell Therapy Features
Figure 6. Other Features
Figure 7. Global Tumor Immunotherapy Market Share by Application in 2021 & 2028
Figure 8. Biopharmaceutical Company Case Studies
Figure 9. Hospital Case Studies
Figure 10. Universities And Other Scientific Research Institutions Case Studies
Figure 11. Other Case Studies
Figure 12. Tumor Immunotherapy Report Years Considered
Figure 13. Global Tumor Immunotherapy Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 14. Global Tumor Immunotherapy Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Tumor Immunotherapy Market Share by Region: 2021 VS 2028
Figure 16. Global Tumor Immunotherapy Market Share by Players in 2021
Figure 17. Global Top Tumor Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunotherapy as of 2021)
Figure 18. The Top 10 and 5 Players Market Share by Tumor Immunotherapy Revenue in 2021
Figure 19. North America Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. North America Tumor Immunotherapy Market Share by Country (2017-2028)
Figure 21. United States Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Canada Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Tumor Immunotherapy Market Share by Country (2017-2028)
Figure 25. Germany Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. France Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. U.K. Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Italy Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Russia Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Nordic Countries Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Tumor Immunotherapy Market Share by Region (2017-2028)
Figure 33. China Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Japan Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. South Korea Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Southeast Asia Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. India Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Australia Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Latin America Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Latin America Tumor Immunotherapy Market Share by Country (2017-2028)
Figure 41. Mexico Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Brazil Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Middle East & Africa Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Middle East & Africa Tumor Immunotherapy Market Share by Country (2017-2028)
Figure 45. Turkey Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Saudi Arabia Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Roche Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 48. Merck Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 49. Novartis Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 50. Johnson & Johnson Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 51. GlaxoSmithKline Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 52. AbbVie Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 53. ELI Lilly Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 54. Amgen Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 55. AstraZeneca Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 56. Bristol-Mysers Squibb Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 57. Kite Pharma Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 58. Adaptimmune Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 59. Altor Bioscience Corporation Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 60. Cellectis Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 61. Juno Therapeutics Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 62. Takara Bio Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 63. Unum Therapeutics Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 64. Sunway Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 65. Junshi Bio Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 66. Cinda Bio Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 67. BeiGene Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029

Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118

The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......

Global Non-imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95

The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90

The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......

Global PCR Equipment Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77

The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......

Global Disposable Sterile Syringes and Needles Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109

The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......

Global Orthopaedic Power Tools Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......

Global Cerebrospinal Fluid Management Devices Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......

Global CAD & CAM Milling Burs Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79

The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......

Global Artificial Teeth Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98

The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs